Tag: clinical trials
-
Immunotherapy Biotech Raising $45 Million in IPO
12 March 2015. Genocea Biosciences Inc., a biotechnology company developing immunotherapies to treat genital herpes and other diseases, is raising $45 million in its initial public offering of stock. The Cambridge, Massachusetts enterprise is issuing 5,454,545 shares priced at $8.25. The company trades on the NASDAQ exchange under the symbol GNCA. As of 12:00 pm…
-
Trial Shows Current Drug Slows Alzheimer’s Onset
11 March 2015. A clinical trial testing a current drug to treat epilepsy shows the drug can delay development of Alzheimer’s disease in its earliest stages. Results of the study, conducted by researchers at Johns Hopkins University for AgeneBio Inc., two year-old pharmaceutical company in Baltimore, appear online in the journal NeuroImage: Clinical. The intermediate-stage…
-
FDA Approves Antibody for Childhood Nerve Cell Cancer
10 March 2015. The U.S. Food and Drug Administration approved today dinutuximab, an engineered antibody to treat neuroblastoma, a rare cancer affecting nerve cells in young children. Dinutuximab is developed by United Therapeutics, a biotechnology company in Silver Spring, Maryland and marketed under the brand name Unituxin. Neuroblastoma is a cancer that develops from immature…
-
Trial Testing Stem Cell Therapy for Spinal Cord Injury
5 March 2015. A clinical trial testing a stem cell therapy for spinal cord injury is recruiting patients at an Atlanta rehabilitation center. The intermediate-stage trial, conducted by biotechnology company Asterias Biotherapeutics, aims to initially enroll 13 adults to test three dosage levels of neural stem cells designed to restore motor functions to spinal cord…
-
Trial to Test Video Game Therapy for Autism
2 March 2015. A clinical trial plans to begin recruiting participants to test a video game designed to engage areas of the brain for building cognitive skills affected by autism. The trial, conducted by Akili Interactive Labs that developed the game, is funded by Delivering Scientific Innovation for Autism or Delsia LLC, a subsidiary of the…
-
Bristol-Myers Squibb Acquires Biotech Cancer Therapies
24 February 2015. Bristol-Myers Squibb is purchasing biotechnology company Flexus Biosciences Inc., gaining many of that company’s cancer therapies in a deal valued as much as $1.25 billion to Flexus’s shareholders. The deal allows Flexus Biosciences shareholders to spin-off a new enterprise to develop the remaining drug programs, including treatments for cancer. The acquisition gives…
-
RNA Flu Therapy Clinical Trials Complete Enrollment
19 February 2015. Two late-stage clinical trials testing an influenza treatment that disrupts a virus’s genetic replication ability finished recruiting more than 2,000 participants worldwide. The trials are being conducted by MediVector Inc., a drug development company in Boston, for Joint Project Manager Medical Countermeasure Systems, an office in the U.S. Department of Defense developing…
-
European Patent Issued for Rare Liver Disease Drug
18 February 2015. Synageva BioPharma Corp., a biopharmaceutical company developing therapies for rare diseases, received a European patent on its treatment for lysosomal acid lipase deficiency, an inherited disease causing severe disruptions and injuries to the liver. The European Patent Office issued patent number EP2613798 B1 on 11 February to inventor Anthony Quinn, Synageva’s chief…
-
Thyroid Cancer Drug Approved by FDA
16 February 2015. The U.S. Food and Drug Administration approved on Friday a drug for differentiated thyroid cancers, where the cancer continues to grow despite treatments with radioactive iodine. The drug, lenvatinib, is marketed by Eisai Inc. in Woodcliffe, New Jersey, under the brand name Lenvima. The thyroid gland helps the body regulate metabolism, using…
-
Biotech, Hospira to Partner on Biosimilar for Eye Disease
10 February 2015. Pfenex Inc., a biotechnology company in San Diego, is licensing its lead product to treat age-related macular degeneration to biologic therapy maker Hospira. The deal can bring Pfenex as much as $342 million, plus royalties on sales of products from the collaboration, over at least the next five years. Age-related macular degeneration is…